Effects of Gastroesophageal Reflux Disease on Sleep and Outcomes

 Conflicts of interest The authors disclose the following: Reema Mody is an employee of Takeda Pharmaceuticals North America, Inc, Deerfield, IL. (At the time of study conduct and analysis she was an employee of TAP Pharmaceutical Products Inc, Lake Forest, IL, now a part of Takeda Pharmaceuticals North America, Inc). Susan C. Bolge is an employee of Consumer Health Sciences, Princeton, NJ. Hema Kannan is an employee of Consumer Health Sciences, Princeton, NJ. Ronnie Fass serves as a consultant to Takeda, AstraZeneca, GSK, P&G, Adelex, Pfizer, Vecta, Eisai, and Salix. He has research funding from Takeda, Wyeth, AstraZeneca, and Sucampo.

 Funding The National Health and Wellness Survey (NHWS) is conducted and wholly owned by Consumer Health Sciences, Princeton, NJ. TAP Pharmaceutical Products Inc, Lake Forest, IL (TAP Pharmaceutical Products, Inc is now a part of Takeda Pharmaceutical North America, Inc) licensed access to NHWS and funded the analysis for and preparation of this article.

PII: S1542-3565(09)00333-4

doi:10.1016/j.cgh.2009.04.005

© 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.